B
Bull
Bull · 25%QNRX
$8.61
Scenario price
$6.120
+1.146 (+18.72%)At close
Loading chart…
- High
- 8.250
- Open
- 7.220
- VWAP
- 6.77
- Vol
- 31.02M
- Mkt Cap
- 2.35M
- Low
- 5.950
- Amount
- 210.09M
- EV/EBITDA, TTM
- 0.00
Quoin Pharmaceuticals Ltd, former Cellect Biotechnology Ltd, is an Israel-based specialty pharmaceutical company, focused on developing and commercializing therapeutic products that treat rare and orphan diseases. The Company’s first lead product is QRX003, a once daily, topical lotion comprised of a broad-spectrum serine protease inhibitor, formulated with the proprietary Invisicare technology, to treat Netherton Syndrome. The product going to be developed for other rare dermatological diseases including Peeling Skin Syndrome, SAM Syndrome, and Palmoplantar Keratoderma. Quoin is also developing QRX004 as a potential treatment for Dystrophic Epidermolysis Bullosa, and QRX006 as a potential therapy for an, as of yet, undisclosed rare skin disease.
AI analysis of Quoin Pharmaceuticals Ltd (QNRX)
buyQuoin Pharmaceuticals is a good buy right now due to its recent positive clinical trial results for QRX003, which showed that 66.7% of patients achieved significant improvements. The stock surged 45% in pre-market trading, indicating strong investor sentiment. Additionally, the current price is $6.12, which is well below the analyst price target of $30, suggesting substantial upside potential. However, the company has reported consistent net losses, with a net income of -5,371,042 USD in Q2 2026, which poses a risk to investors.
Valuation Metrics
The current forward P/E ratio for Quoin Pharmaceuticals Ltd (QNRX) is 0.00, compared to its 5-year average forward P/E of -1.10.
Alphio AI Price Scenarios for QNRX
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Events Timeline
News
9.508-28NASDAQ.COMQuoin Pharmaceuticals Reports Positive Interim Results for QRX003
8.508-28NewsfilterQuoin Pharmaceuticals Raises $50 Million in Securities Purchase Agreement
- 9.508-07Newsfilter
Quoin Pharmaceuticals to Release Q2 2026 Financial Results and Corporate Update
9.007-09NASDAQ.COMQuoin Pharmaceuticals Receives FDA Clearance for Clinical Trial
- 9.007-09Newsfilter
Quoin Pharmaceuticals Receives FDA Approval to Initiate Clinical Trial for Peeling Skin Syndrome
QNRX FAQ — answered by Alphio AI
Quoin Pharmaceuticals Ltd, former Cellect Biotechnology Ltd, is an Israel-based specialty pharmaceutical company, focused on developing and commercializing therapeutic products that treat rare and orphan diseases. The Company’s first lead product is QRX003, a once daily, topical lotion comprised of a broad-spectrum serine protease inhibitor, formulated with the proprietary Invisicare technology, to treat Netherton Syndrome. The product going to be developed for other rare dermatological diseases including Peeling Skin Syndrome, SAM Syndrome, and Palmoplantar Keratoderma. Quoin is also developing QRX004 as a potential treatment for Dystrophic Epidermolysis Bullosa, and QRX006 as a potential therapy for an, as of yet, undisclosed rare skin disease. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Quoin Pharmaceuticals is a good buy right now due to its recent positive clinical trial results for QRX003, which showed that 66.7% of patients achieved significant improvements. The stock surged 45% in pre-market trading, indicating strong investor sentiment. Additionally, the current price is $6.12, which is well below the analyst price target of $30, suggesting substantial upside potential. However, the company has reported consistent net losses, with a net income of -5,371,042 USD in Q2 2026, which poses a risk to investors.
本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。